The editorial discusses the beneficial effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with diabetic nephropathy and their underutilization in government hospitals in India for the treatment of diabetic nephropathy. The authors provide a comprehensive analysis of various factors contributing to the under-prescription of these medications, including lack of awareness and education among healthcare professionals, limited availability and accessibility of medications, high cost, and poor adherence to evidence-based guidelines. This evidence concerns the gene SLC5A2 and diabetic kidney disease.